Procurement teams evaluating DSIP (5mg / 15mg) in Neuropeptide Research programs can use this spec alignment brief before requesting a quote on sulanpeptide.vip.
DSIP, short for Delta Sleep-Inducing Peptide, is a synthetic neuropeptide used in laboratory research on neuroendocrine signaling, circadian-regulation models, stress-response pathways, and peptide activity within sleep-related research systems.
Original DSIP isolation papers from the 1970s–80s established its neuropeptide identity; modern work focuses on receptor-independent versus receptor-mediated hypotheses. Delta Sleep-Inducing Peptide (DSIP) is studied for effects on sleep-architecture EEG patterns in rodent polysomnography models and on stress-hormone oscillations in hypothalamic slice preparations.
Mechanism hypotheses include modulation of NMDA receptor subunit phosphorylation and circadian gene expression in suprachiasmatic nucleus explants. EEG/EMG sleep scoring, cortisol rhythm sampling in animal models, and neuropeptide release microdialysis are documented experimental approaches.
Principal investigators should sign off DSIP SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (5mg / 15mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for DSIP.
Catalog identifiers for DSIP: CAS 62568-57-4, Formula: C35H48N10O15. MW 848.8 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Dose planning for DSIP should state mass (5mg / 15mg) or molarity derived from catalog molecular weight.
Publication methods should list Cat No. and mg strength for DSIP to support reproducibility.
Format selection for DSIP affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for DSIP. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for DSIP should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type. Specification alignment for DSIP requires copying exact kit notation (5mg / 15mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for DSIP—CAS 62568-57-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing DSIP should include these fields for reproducibility in Neuropeptide Research journals.
Specification alignment for DSIP requires copying exact kit notation (5mg / 15mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for DSIP—CAS 62568-57-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing DSIP should include these fields for reproducibility in Neuropeptide Research journals.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for DSIP should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
DSIP from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.